Rubius Therapeutics (NASDAQ:RUBY) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Rubius Therapeutics (NASDAQ:RUBY) issued its earnings results on Thursday, March 28th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.07, MarketWatch Earnings reports.

Shares of RUBY traded down $0.70 during trading hours on Friday, hitting $17.04. The stock had a trading volume of 153,239 shares, compared to its average volume of 263,301. The company has a current ratio of 20.72, a quick ratio of 20.72 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.36 billion and a P/E ratio of -7.51. Rubius Therapeutics has a 12-month low of $12.70 and a 12-month high of $33.01.

Separately, Zacks Investment Research lowered Rubius Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Rubius Therapeutics has an average rating of “Buy” and an average price target of $30.00.

In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 48,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $15.84, for a total value of $760,320.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Torben Straight Nissen sold 2,100 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $20.00, for a total value of $42,000.00. The disclosure for this sale can be found here. Insiders sold a total of 70,196 shares of company stock worth $1,186,015 over the last ninety days. Corporate insiders own 58.40% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in RUBY. BlackRock Inc. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $38,155,000. New York State Common Retirement Fund purchased a new stake in shares of Rubius Therapeutics during the fourth quarter worth about $116,000. Marshall Wace North America L.P. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $1,405,000. Teachers Advisors LLC purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $563,000. Finally, Baillie Gifford & Co. purchased a new stake in shares of Rubius Therapeutics during the third quarter worth about $93,831,000. 87.07% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/21/rubius-therapeutics-ruby-posts-earnings-results-beats-estimates-by-0-07-eps.html.

Rubius Therapeutics Company Profile

Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.

Further Reading: Growth and Income Funds

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.